Initiates cell line development for lead BiTAC-TCE program with ATUM; Stable clonal cell line generation to support CMC development and nonc
VERAXA Biotech AG engaged ATUM to apply Leap-In Transposase technology to support stable clonal cell line generation for its lead BiTAC-T-cell engager (BiTAC-TCE) program - The generated clonal cell lines are intended for use throughout CMC development, including early process, analytical, and formulation development, and to supply material for nonclinical studies - Company says BiTAC-TCE uses an “AND”-gated mechanism designed to activate CD3 only when both tumor markers are present on the same cell, aiming to improve selectivity
VERAXA Biotech AG engaged ATUM to apply Leap-In Transposase technology to support stable clonal cell line generation for its lead BiTAC-T-cell engager (BiTAC-TCE) program - The generated clonal cell lines are intended for use throughout CMC development, including early process, analytical, and formulation development, and to supply material for nonclinical studies - Company says BiTAC-TCE uses an “AND”-gated mechanism designed to activate CD3 only when both tumor markers are present on the same cell, aiming to improve selectivity